Biocon founder Kiran Mazumdar Shaw says she is confident that the company’s investment and capacity expansion in Insulin will make the company the top hub for the drug in the next five years. She speaks in an exclusive conversation with Bloomberg’s Haslinda Amin. (Source: Bloomberg)
Trending
- Bitcoin ETF inflow rebounds, but Fidelity supplied 81.5%
- My co-workers complain about minor things and make every meeting miserable. How should I deal with them?
- US data mixed as Iran headlines and Canada tariffs dominate
- Mortgage rates could move even higher — dealing a fresh blow to home buyers
- Synchrony, card issuer to Amazon, partners with OpenAI for ChatGPT shopping
- Strategy’s Future Hinges on Bitcoin Becoming a Real Currency: Jeff Booth
- 13F Season: Where Wall Street’s Smart Money is Betting
- Elliptic Upgrades Continuous Monitoring to Cut Crypto Alert
Wednesday, August 19
